clinical trial · NCT06940141
Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)
Connect Biopharm LLC·phase2·recruiting·n = 160
Asthma AcuteRademikibart in prefilled syringeMatching placebo in prefilled syringe
brief summary
This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation
started
Aug 8, 2025
primary completion
Apr 1, 2026
completion
May 1, 2026
last updated
Mar 31, 2026
detailed description
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, interventional trial in participants with an acute asthma exacerbation with type 2 inflammation to compare rademikibart plus standard therapy to standard therapy alone (plus placebo), targeting an acute asthma exacerbation in the urgent healthcare setting.
official title
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Adult and Adolescent Participants With Asthma and Type 2 Inflammation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol